Axovant: That positive p-value we reported yesterday? Um, we screwed that up too
Yesterday Axovant execs watched their stock price $AXON collapse after the biotech founded by the youthful former hedge fund manager Vivek Ramaswamy was forced to concede that its lead drug was worthless.
Today, the company led by CEO David Hung followed up with the extraordinarily embarrassing admission that it managed to incorrectly report the p value for the one clearly positive endpoint they had touted as a sign that the biotech’s second drug, nelotanserin, was worthy of a pivotal trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.